BusinessBeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology SymposiumBy Nasdaq OMXJan 26, 2018, 1:01 PM UTC
BusinessBeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)By Nasdaq OMXDec 14, 2017, 1:01 PM UTC
BusinessBeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in ChinaBy Nasdaq OMXDec 4, 2017, 12:00 PM UTC
BusinessBeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate SuperiorityBy Nasdaq OMXNov 30, 2017, 2:58 PM UTC
BusinessBeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced NeutropeniaBy Nasdaq OMXOct 26, 2017, 12:31 PM UTC
BusinessBeyondSpring Receives Two Grants in China to Further Develop Innovative Drug PipelineBy Nasdaq OMXOct 23, 2017, 12:31 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San FranciscoBy Nasdaq OMXOct 18, 2017, 12:30 PM UTC
BusinessChina FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia PreventionBy Nasdaq OMXJul 6, 2017, 12:00 PM UTC
